GSK 6-K
GSK plc (GSK)
6-K
2026-01-13
For: 2026-01-13
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
|---|---|---|---|---|---|
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief<br>Executive Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 3 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 32 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 4 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Neil Falkingham | |||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 53 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 9 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | David Redfern | |||
| b) | Position/status | President<br>Corporate Development | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 67 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Regis Simard | |||
| b) | Position/status | President,<br>Global Supply Chain | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 26 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Philip Thomson | |||
| b) | Position/status | President,<br>Global Affairs | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 43 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO,<br>ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 56 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Victoria Whyte | |||
| b) | Position/status | SVP<br>& Company Secretary | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026 on shares held<br>through the Company's Share Reward Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9433 | 52 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 147.920 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 1,077.932 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Mike Crichton | |||
| b) | Position/status | President, International | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 1.368 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Neil Falkingham | |||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 66.402 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 895.632 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Nina Mojas | |||
| b) | Position/status | President, Global Product Strategy | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 0.006 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | David Redfern | |||
| b) | Position/status | President Corporate Development | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 5,487.904 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 1,974.570 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Philip Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 1,874.766 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Kate Thomson | |||
| b) | Position/status | PCA of Philip Thomson (President, Global Affairs) | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 95.614 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 105.088 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 1,110.412 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Victoria Whyte | |||
| b) | Position/status | SVP<br>& Company Secretary | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 109 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Iain Whyte | |||
| b) | Position/status | PCA of Victoria Whyte (SVP & Company Secretary) | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 8 January 2026. | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9464 | 1,008 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-01-08 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | |
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief<br>Executive Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9100 | 506 | ||||
| £18.9100 | 319 | ||||
| £18.9100 | 637 | ||||
| d) | Aggregated<br>information | ||||
| Aggregated<br>volume<br><br>Price | 1,462<br><br><br>18.9100 | ||||
| e) | Date<br>of the transaction | 2026-01-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Julie Brown | ||
| b) | Position/status | Chief Financial Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9100 | 595 | |||
| £18.9100 | 511 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 1,106<br><br><br>18.9100 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Diana Conrad | ||
| b) | Position/status | Chief People Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9100 | 133 | |||
| £18.9100 | 338 | |||
| £18.9100 | 215 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 686<br><br><br>18.9100 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | James Ford | ||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9100 | 342 | |||
| £18.9100 | 208 | |||
| £18.9100 | 210 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 760<br><br><br>18.9100 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Shobie Ramakrishnan | ||
| b) | Position/status | Chief Digital and Technology Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in ADSs following the re-investment<br>of dividends paid to shareholders on 8 January 2026 on ADSs held in<br>the Company's Deferred Annual Bonus Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $50.2200 | 105 | |||
| $50.2200 | 98 | |||
| $50.2200 | 163 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 366<br><br><br>50.2200 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) |
All values are in US Dollars.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | David Redfern | ||
| b) | Position/status | President,<br>Corporate Development | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9100 | 292 | |||
| £18.9100 | 405 | |||
| £18.9100 | 184 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 881<br><br><br>18.9100 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Regis Simard | ||
| b) | Position/status | President, Global Supply Chain | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9100 | 270 | |||
| £18.9100 | 488 | |||
| £18.9100 | 235 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 993<br><br><br>18.9100 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Philip Thomson | ||
| b) | Position/status | President, Global Affairs | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9100 | 164 | |||
| £18.9100 | 153 | |||
| £18.9100 | 273 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 590<br><br><br>18.9100 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Deborah Waterhouse | ||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9100 | 422 | |||
| £18.9100 | 374 | |||
| £18.9100 | 254 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 1,050<br><br><br>18.9100 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Tony Wood | ||
| b) | Position/status | Chief Scientific Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 8 January 2026<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9100 | 237 | |||
| £18.9100 | 520 | |||
| £18.9100 | 177 | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 934<br><br><br>18.9100 | |||
| e) | Date<br>of the transaction | 2026-01-09 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details<br>of PDMR/person closely associated with them ('PCA') | ||||
|---|---|---|---|---|---|
| a) | Name | Elizabeth<br>McKee Anderson | |||
| b) | Position/status | Independent<br>Non-Executive Director | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details<br>of the issuer, emission allowance market participant, auction<br>platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details<br>of the transaction(s): section to be repeated for (i) each type of<br>instrument; (ii) each type of transaction; (iii) each date; and<br>(iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description of the<br>financial instrument | American<br>Depositary Shares ('ADSs')<br><br>ISIN:<br>US37733W2044 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 8 January 2026 | |||
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) | ||
| $50.4345 | 25 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date of<br>the transaction | 2026-01-09 | |||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | |||
| 1. | Details<br>of PDMR/person closely associated with them ('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Charles<br>Bancroft | |||
| b) | Position/status | Senior<br>Independent Non-Executive Director | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details<br>of the issuer, emission allowance market participant, auction<br>platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details<br>of the transaction(s): section to be repeated for (i) each type of<br>instrument; (ii) each type of transaction; (iii) each date; and<br>(iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description of the<br>financial instrument | American<br>Depositary Shares ('ADSs')<br><br>ISIN:<br>US37733W2044 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 8 January 2026 | |||
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) | ||
| $50.4345 | 316 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date of<br>the transaction | 2026-01-09 | |||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | |||
| 1. | Details<br>of PDMR/person closely associated with them ('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Dr Hal<br>Barron | |||
| b) | Position/status | Non-Executive<br>Director | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details<br>of the issuer, emission allowance market participant, auction<br>platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details<br>of the transaction(s): section to be repeated for (i) each type of<br>instrument; (ii) each type of transaction; (iii) each date; and<br>(iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description of the<br>financial instrument | American<br>Depositary Shares ('ADSs')<br><br>ISIN:<br>US37733W2044 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 8 January 2026 | |||
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) | ||
| $50.4345 | 28 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date of<br>the transaction | 2026-01-09 | |||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | |||
| 1. | Details<br>of PDMR/person closely associated with them ('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Dr Anne<br>Beal | |||
| b) | Position/status | Independent<br>Non-Executive Director | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details<br>of the issuer, emission allowance market participant, auction<br>platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details<br>of the transaction(s): section to be repeated for (i) each type of<br>instrument; (ii) each type of transaction; (iii) each date; and<br>(iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description of the<br>financial instrument | American<br>Depositary Shares ('ADSs')<br><br>ISIN:<br>US37733W2044 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 8 January 2026 | |||
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) | ||
| $50.4345 | 31 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date of<br>the transaction | 2026-01-09 | |||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | |||
| 1. | Details<br>of PDMR/person closely associated with them ('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Dr<br>Harry Dietz | |||
| b) | Position/status | Independent<br>Non-Executive Director | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details<br>of the issuer, emission allowance market participant, auction<br>platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details<br>of the transaction(s): section to be repeated for (i) each type of<br>instrument; (ii) each type of transaction; (iii) each date; and<br>(iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description of the<br>financial instrument | American<br>Depositary Shares ('ADSs')<br><br>ISIN:<br>US37733W2044 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 8 January 2026 | |||
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) | ||
| $50.4345 | 31 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date of<br>the transaction | 2026-01-09 | |||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | |||
| 1. | Details<br>of PDMR/person closely associated with them ('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Dr<br>Jeannie Lee | |||
| b) | Position/status | Independent<br>Non-Executive Director | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details<br>of the issuer, emission allowance market participant, auction<br>platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details<br>of the transaction(s): section to be repeated for (i) each type of<br>instrument; (ii) each type of transaction; (iii) each date; and<br>(iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description of the<br>financial instrument | American<br>Depositary Shares ('ADSs')<br><br>ISIN:<br>US37733W2044 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 8 January 2026 | |||
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) | ||
| $50.4345 | 13 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date of<br>the transaction | 2026-01-09 | |||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | |||
| 1. | Details<br>of PDMR/person closely associated with them ('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Dr<br>Vishal Sikka | |||
| b) | Position/status | Independent<br>Non-Executive Director | |||
| c) | Initial<br>notification/amendment | Initial<br>notification | |||
| 2. | Details<br>of the issuer, emission allowance market participant, auction<br>platform, auctioneer or auction monitor | ||||
| a) | Name | GSK<br>plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details<br>of the transaction(s): section to be repeated for (i) each type of<br>instrument; (ii) each type of transaction; (iii) each date; and<br>(iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description of the<br>financial instrument | American<br>Depositary Shares ('ADSs')<br><br>ISIN:<br>US37733W2044 | |||
| b) | Nature<br>of the transaction | Acquisition<br>of ADSs following the re-investment of dividends paid to<br>shareholders on 8 January 2026 | |||
| c) | Price(s) and<br>volume(s) | Price(s) | Volume(s) | ||
| $50.4345 | 94 | ||||
| d) | Aggregated<br>information | N/A<br>(single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date of<br>the transaction | 2026-01-09 | |||
| f) | Place<br>of the transaction | New<br>York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | |
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £18.9321 | 6 (partnership shares) | ||||
| £18.9321 | 6 (matching shares) | ||||
| d) | Aggregated<br>information | ||||
| Aggregated<br>volume<br><br>Price | 12 Ordinary Shares<br><br><br>18.9321 | ||||
| e) | Date<br>of the transaction | 2026-01-12 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Julie Brown | ||
| b) | Position/status | Chief<br>Financial Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9321 | 7 (partnership shares) | |||
| £18.9321 | 7 (matching shares) | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 14 Ordinary Shares<br><br><br>18.9321 | |||
| e) | Date<br>of the transaction | 2026-01-12 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Neil Falkingham | ||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9321 | 6 (partnership shares) | |||
| £18.9321 | 6 (matching shares) | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 12 Ordinary Shares<br><br><br>18.9321 | |||
| e) | Date<br>of the transaction | 2026-01-12 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | James Ford | ||
| b) | Position/status | SVP and<br>Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9321 | 7 (partnership shares) | |||
| £18.9321 | 7 (matching shares) | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 14 Ordinary Shares<br><br><br>18.9321 | |||
| e) | Date<br>of the transaction | 2026-01-12 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | David Redfern | ||
| b) | Position/status | President,<br>Corporate Development | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9321 | 7 (partnership shares) | |||
| £18.9321 | 7 (matching shares) | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 14 Ordinary Shares<br><br><br>18.9321 | |||
| e) | Date<br>of the transaction | 2026-01-12 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Regis Simard | ||
| b) | Position/status | President,<br>Global Supply Chain | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9321 | 6 (partnership shares) | |||
| £18.9321 | 6 (matching shares) | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 12 Ordinary Shares<br><br><br>18.9321 | |||
| e) | Date<br>of the transaction | 2026-01-12 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Philip Thomson | ||
| b) | Position/status | President,<br>Global Affairs | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9321 | 6 (partnership shares) | |||
| £18.9321 | 6 (matching shares) | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 12 Ordinary Shares<br><br><br>18.9321 | |||
| e) | Date<br>of the transaction | 2026-01-12 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Deborah Waterhouse | ||
| b) | Position/status | CEO,<br>ViiV Healthcare and President, Global Health, GSK | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9321 | 6 (partnership shares) | |||
| £18.9321 | 6 (matching shares) | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 12 Ordinary Shares<br><br><br>18.9321 | |||
| e) | Date<br>of the transaction | 2026-01-12 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Victoria Whyte | ||
| b) | Position/status | SVP<br>& Company Secretary | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £18.9321 | 7 (partnership shares) | |||
| £18.9321 | 7 (matching shares) | |||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br>Price | 14 Ordinary Shares<br><br><br>18.9321 | |||
| e) | Date<br>of the transaction | 2026-01-12 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: 13<br>January 2026 | |
| By:/s/ VICTORIA<br>WHYTE<br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |